ERBB2 and breast carcinoma: Among them, one successful culture model was derived from a non-pCR breast cancer tissue specimen obtained after trastuzumab-based neoadjuvant therapy, which reflected the biological characteristics of intrinsic anti-HER2 resistant breast cancer.